DRI12544 (18+ years), QUEST (12+ years), VOYAGE (6-11 years)

The most common adverse reactions from the DUPIXENT asthma trials were injection site reactions,^l oropharyngeal pain, and eosinophilia.^m These adverse reactions occurred in ≥1% of patients receiving DUPIXENT + SOC and at a higher rate than in patients receiving placebo + SOC in DRI12544 and QUEST (6-month safety pool).¹

The safety profile of DUPIXENT through Week 52 was similar to the safety profile from studies in adult and pediatric subjects 12 years of age and older with moderate-to-severe asthma with the addition of helminth infections.¹